The Moving Average Convergence Divergence (MACD) for RGEN turned positive on January 07, 2025. Looking at past instances where RGEN's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on January 03, 2025. You may want to consider a long position or call options on RGEN as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
RGEN moved above its 50-day moving average on January 03, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in of 349 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 225 cases where RGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.181) is normal, around the industry mean (23.475). P/E Ratio (247.520) is within average values for comparable stocks, (83.627). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (16.155) is also within normal values, averaging (41.274).
a developer of biologic drugs
Industry MedicalSpecialties
A.I.dvisor indicates that over the last year, RGEN has been loosely correlated with BIO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RGEN jumps, then BIO could also see price increases.
Ticker / NAME | Correlation To RGEN | 1D Price Change % | ||
---|---|---|---|---|
RGEN | 100% | +3.53% | ||
BIO - RGEN | 56% Loosely correlated | +0.78% | ||
WAT - RGEN | 47% Loosely correlated | +1.94% | ||
MTD - RGEN | 47% Loosely correlated | +1.39% | ||
BLFS - RGEN | 47% Loosely correlated | -0.97% | ||
IQV - RGEN | 45% Loosely correlated | +0.80% | ||
More |